Home > Pulmonology > ATS 2019 > COPD > CORTICO-COP Trial: Eosinophil-guided Therapy Reduces Systemic Corticosteroid Exposure

CORTICO-COP Trial: Eosinophil-guided Therapy Reduces Systemic Corticosteroid Exposure

Presented By
Dr Pradeesh Sivapalan, University of Copenhagen, Denmark
Conference
ATS 2019
Trial
CORTICO-COP

Results of the CORTICO-COP trial that administering systemic corticosteroid prednisolone only on days when blood eosinophil count was at least 0.3 x 109 cells/L in patients with chronic obstructive pulmonary disease (COPD) significantly reduced systemic corticosteroid exposure; although this strategy did not confer a benefit in terms of the number of days alive and out of hospital.

Dr Pradeesh Sivapalan (University of Copenhagen, Denmark) presented the research in a late-breaking clinical trial session, noting that the work was being simultaneously published in The Lancet Respiratory Medicine [1,2]. Corticosteroids are frequently used in the treatment of acute COPD exacerbations. However, the use of systemic corticosteroids is not without risks. As such, strategies to limit systemic corticosteroid exposure are needed. In this multicentre randomised controlled trial, 318 patients age 4...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on